Dolutegravir plus Rilpivirine: Benefits Beyond Viral Suppression: DORIPEX Retrospective Study


In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control.